One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1182/blood.v128.22.215.215
Copy DOI Journal: Blood |  Publication Date: Dec 2, 2016 |
 Citations: 25 |
Affiliation: Dana-Farber Cancer Institute, City of Hope, Hackensack University Medical Center, Roswell Park Cancer Institute, Ark Therapeutic (United States), Colorado Blood Cancer Institute, The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Sarah Cannon, Albert Einstein College of Medicine, Montefiore Medical Center, Cleveland Clinic, Ann Arbor VA Medical Center, University of Michigan–Ann Arbor, Moffitt Cancer Center, Duke University Hospital, Duke Medical Center, Yale UniversityResults from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
